Capricor Therapeutics (NASDAQ:CAPR) Sees Strong Trading Volume - Should You Buy?

Key Points

• Unusually-high trading volume: About 2,454,245 shares traded (a 95% increase from the prior session), with the stock rising from a prior close of $30.63 to around $35.22 during mid-day trading.
• Analyst consensus: Nine analysts rate CAPR a Buy and one a Sell, giving a consensus "Moderate Buy" and a mean target price of $40.82, with some firms issuing $50–$60 targets.
• Company profile & performance: Capricor is a clinical-stage biotech developing cell/exosome therapies (lead candidate CAP-1002 for DMD and cardiac injury); market cap is about $1.58 billion and the 50-day/200-day SMAs ($25.38/$15.93) show recent price strength.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 2,454,245 shares traded hands during mid-day trading, an increase of 95% from the previous session's volume of 1,258,353 shares.The stock last traded at $35.2190 and had previously closed at $30.63.

Analyst Ratings Changes

A number of brokerages have recently commented on CAPR. Wall Street Zen lowered shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, January 11th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Capricor Therapeutics in a research report on Wednesday, January 14th. HC Wainwright reissued a "buy" rating and issued a $60.00 target price on shares of Capricor Therapeutics in a research note on Tuesday. B. Riley Financial restated a "buy" rating and set a $50.00 price target (up from $21.00) on shares of Capricor Therapeutics in a research report on Monday, December 15th. Finally, UBS Group set a $50.00 price objective on Capricor Therapeutics in a report on Monday, December 15th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $40.82.

Capricor Therapeutics Price Performance

The firm's 50 day simple moving average is $25.38 and its two-hundred day simple moving average is $15.93. The firm has a market capitalization of $1.58 billion, a P/E ratio of -19.34 and a beta of 0.37.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. GSA Capital Partners LLP purchased a new position in shares of Capricor Therapeutics in the third quarter worth $1,555,000. Geode Capital Management LLC boosted its position in Capricor Therapeutics by 6.8% during the 2nd quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company's stock valued at $9,565,000 after buying an additional 61,701 shares during the period. HBK Sorce Advisory LLC grew its holdings in Capricor Therapeutics by 33.7% in the 3rd quarter. HBK Sorce Advisory LLC now owns 170,577 shares of the biotechnology company's stock worth $1,141,000 after acquiring an additional 42,951 shares during the last quarter. Citizens Financial Group Inc. RI grew its holdings in Capricor Therapeutics by 249.2% in the 2nd quarter. Citizens Financial Group Inc. RI now owns 35,000 shares of the biotechnology company's stock worth $348,000 after acquiring an additional 24,977 shares during the last quarter. Finally, First Financial Bank Trust Division purchased a new position in shares of Capricor Therapeutics in the third quarter valued at about $203,000. Institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.